ETR:MOR MorphoSys (MOR) Stock Price, News & Analysis → Buy Friday, Sell Monday, No Exceptions (From DTI) (Ad) Free MOR Stock Alerts €67.20 -0.02 (-0.03%) (As of 03/27/2024 ET) Add Compare Share Share Today's Range€67.18▼€67.2650-Day Range€33.42▼€67.2252-Week Range€13.81▼€66.82Volume84,006 shsAverage Volume153,687 shsMarket Capitalization$2.53 billionP/E RatioN/ADividend Yield1.26%Price TargetN/A Stock AnalysisStock AnalysisChartHeadlinesStock AnalysisChartHeadlines Get MorphoSys alerts: Email Address Ad DTIBuy Friday, Sell Monday, No Exceptions Every week traders grind it out Monday through Friday… But neglect trading Friday to Monday… Or… “over the weekend” As one professional trader explains, trading over the weekend is one of the most forgiving strategies you can use today. It allows him to sidestep a lot of the midweek volatility. Yet, gives him the opportunity to target some of the markets biggest stock moves. Just recently, he posted a trade on Nordstrom… The trade was published at 3pm on a Friday afternoon and by Monday morning the trade more than doubled.And for the first time in 2024, he’s sharing his strategy for free. About MorphoSys Stock (ETR:MOR)MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.Read More MOR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MOR Stock News HeadlinesMarch 22, 2024 | markets.businessinsider.comEQS-News: MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR ActMarch 15, 2024 | finance.yahoo.comMorphoSys AG (NASDAQ:MOR) Q4 2023 Earnings Call TranscriptMarch 28, 2024 | DTI (Ad)Warning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…March 13, 2024 | markets.businessinsider.comEQS-News: MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 13, 2024 | benzinga.comMorphoSys: Q4 Earnings InsightsMarch 12, 2024 | msn.comGerman regulators approve Novartis deal to buy drugmaker MorphosysFebruary 15, 2024 | finance.yahoo.comWhat Makes MorphoSys AG Unsponsored ADR (MOR) a Strong Momentum Stock: Buy Now?February 8, 2024 | finance.yahoo.comBiotech Stock Roundup: GILD, AMGN & BMY's Q4 Results, MOR Up on NVS Deal & MoreMarch 28, 2024 | DTI (Ad)Buy Friday, Sell Monday, No Exceptions Every week traders grind it out Monday through Friday… But neglect trading Friday to Monday… Or… “over the weekend” As one professional trader explains, trading over the weekend is one of the most forgiving strategies you can use today. It allows him to sidestep a lot of the midweek volatility. Yet, gives him the opportunity to target some of the markets biggest stock moves. Just recently, he posted a trade on Nordstrom… The trade was published at 3pm on a Friday afternoon and by Monday morning the trade more than doubled.February 7, 2024 | realmoney.thestreet.comMorphoSys just downgraded at JMP Securities, here's whyFebruary 6, 2024 | finance.yahoo.comNovartis (NVS) to Buy MorphoSys & Add Late-Stage Oncology DrugFebruary 6, 2024 | seekingalpha.comNovartis And MorphoSys Are A Perfect MatchFebruary 5, 2024 | finance.yahoo.comNovartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of EUR 2.7bn in cashFebruary 5, 2024 | finance.yahoo.comUPDATE 1-Novartis to acquire cancer drug developer MorphoSys for $2.9 blnFebruary 3, 2024 | morningstar.comMorphoSys AG ADR MORJanuary 31, 2024 | markets.businessinsider.comDAX Edges Higher As Investors Await GDP DataJanuary 30, 2024 | marketwatch.comUS Futures Flat, European Stocks Slightly Down Ahead of Central Bank DecisionsJanuary 30, 2024 | markets.businessinsider.comEuropean Shares Slightly Higher; Flash Eurozone GDP Data AwaitedJanuary 30, 2024 | msn.comMorphoSys expects 2024 Monjuvi U.S. net product sales in $80M - $95M rangeJanuary 30, 2024 | finance.yahoo.comMorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial LiabilityJanuary 30, 2024 | finance.yahoo.comMorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial LiabilityJanuary 18, 2024 | seekingalpha.comMorphoSys: Positive Pelabresib Data Finally Unlocking UpsideJanuary 8, 2024 | markets.businessinsider.comEQS-News: MorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceJanuary 8, 2024 | finance.yahoo.comMorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceDecember 18, 2023 | finance.yahoo.comOptimistic Investors Push MorphoSys AG (ETR:MOR) Shares Up 48% But Growth Is LackingDecember 14, 2023 | markets.businessinsider.comMorphoSys To Issue 3.423 Mln New Shares At EUR 30/shrDecember 14, 2023 | marketwatch.comMorphoSys Shares Fall After Raising Funds to Accelerate Drug Launch, TrialsSee More Headlines Receive MOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MorphoSys and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeETR SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolETR:MOR CUSIPN/A CIKN/A Webwww.morphosys.de Phone+49-89-899270FaxN/AEmployees524Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)(€5.53) Trailing P/E RatioN/A Forward P/E Ratio326.86 P/E Growth0.06Net Income$-189,730,000.00 Net Margins-79.63% Pretax MarginN/A Return on Equity-183.80% Return on Assets-6.82% Debt Debt-to-Equity Ratio526.17 Current Ratio3.08 Quick Ratio3.49 Sales & Book Value Annual Sales$238.28 million Price / Sales10.60 Cash Flow€129.63 per share Price / Cash Flow0.52 Book Value€1.30 per share Price / Book51.69Miscellaneous Outstanding Shares37,600,000Free FloatN/AMarket Cap$2.53 billion OptionableNot Optionable Beta0.61 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Jean-Paul Kress M.D. (Age 59)Chairman of Management Board, MD & CEO Comp: $1.76MDr. Lucinda Crabtree Ph.D. (Age 45)CFO & Member of Management Board Comp: $705.82kMs. Charlotte Lohmann (Age 54)Chief Legal and Human Resources Officer & Member of Management Board Comp: $474.1kMr. Klaus De WallHead of Accounting & TaxDr. Margit UrbanHead of Discovery Alliances & TechnologiesDr. Julia Neugebauer Ph.D.Head of Investor RelationsDr. Barbara Krebs-Pohl Ph.D.Chief Business OfficerDr. Günter WellnhoferHead of Technical OperationsDr. Harald WatzkaHead of Alliance ManagementMs. Yen Ching ChuaHead of Clinical OperationsMore ExecutivesKey CompetitorsBiotest AktiengesellschaftETR:BIOEvotecETR:EVTShop Apotheke EuropeETR:SAEGerresheimerETR:GXICompuGroup Medical SE & Co. KGaAETR:COPView All Competitors MOR Stock Analysis - Frequently Asked Questions How have MOR shares performed in 2024? MorphoSys' stock was trading at €34.00 at the start of the year. Since then, MOR shares have increased by 97.6% and is now trading at €67.20. View the best growth stocks for 2024 here. What other stocks do shareholders of MorphoSys own? Based on aggregate information from My MarketBeat watchlists, some companies that other MorphoSys investors own include Novo Nordisk A/S (NVO), Gilead Sciences (GILD), SolarEdge Technologies (SEDG), Supernus Pharmaceuticals (SUPN), AbbVie (ABBV), Abbott Laboratories (ABT), MercadoLibre (MELI), Neurocrine Biosciences (NBIX), Nightstar Therapeutics (NITE) and NVIDIA (NVDA). This page (ETR:MOR) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MorphoSys AG Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.